Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MaxCyte ( (MXCT) ) has shared an update.
MaxCyte, Inc. has announced a change in major holdings, with BlackRock, Inc., a significant investor, acquiring additional voting rights. This adjustment reflects a slight increase in BlackRock’s stake, now totaling 7.60% of MaxCyte’s voting rights, indicating continued confidence and investment interest in MaxCyte’s business by major institutional investors.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell engineering technology and providing platforms for cell-based therapies and gene editing. They cater to a global market with applications in drug development and manufacturing.
YTD Price Performance: 24.69%
Average Trading Volume: 60,907
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £436.3M
For a thorough assessment of MXCT stock, go to TipRanks’ Stock Analysis page.
